121 related articles for article (PubMed ID: 35857974)
21. Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma.
Ghassemi F; Shields CL; Ghadimi H; Khodabandeh A; Roohipoor R
JAMA Ophthalmol; 2014 Aug; 132(8):936-41. PubMed ID: 24789622
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and toxicity of second-course ophthalmic artery chemosurgery for retinoblastoma.
Francis JH; Abramson DH; Gobin YP; Marr BP; Tendler I; Brodie SE; Dunkel IJ
Ophthalmology; 2015 May; 122(5):1016-22. PubMed ID: 25616769
[TBL] [Abstract][Full Text] [Related]
23. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results.
Abramson DH; Dunkel IJ; Brodie SE; Kim JW; Gobin YP
Ophthalmology; 2008 Aug; 115(8):1398-404, 1404.e1. PubMed ID: 18342944
[TBL] [Abstract][Full Text] [Related]
24. Pathological findings in enucleated eyes after intravitreal melphalan injection.
Ghassemi F; Amoli FA
Int Ophthalmol; 2014 Jun; 34(3):533-40. PubMed ID: 24043335
[TBL] [Abstract][Full Text] [Related]
25. [Study on conservative treatment of retinoblastoma--effect of intravitreal injection of melphalan on the rabbit retina].
Ueda M; Tanabe J; Inomata M; Kaneko A; Kimura T
Nippon Ganka Gakkai Zasshi; 1995 Nov; 99(11):1230-5. PubMed ID: 8533651
[TBL] [Abstract][Full Text] [Related]
26. Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review.
Smith SJ; Smith BD; Mohney BG
Br J Ophthalmol; 2014 Mar; 98(3):292-7. PubMed ID: 24187047
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds.
Abramson DH; Ji X; Francis JH; Catalanotti F; Brodie SE; Habib L
Br J Ophthalmol; 2019 Apr; 103(4):488-493. PubMed ID: 29875233
[TBL] [Abstract][Full Text] [Related]
28. Addition of intravitreal carboplatin with melphalan for management of vitreous seeding in retinoblastoma.
Riazi-Esfahani H; Masoomian B; Khodabandeh A; Amini A; Taghizadeh S; Boujabadi L; Sharifkashani S; Shields CL; Ghassemi F
Graefes Arch Clin Exp Ophthalmol; 2023 Apr; 261(4):1167-1175. PubMed ID: 36401651
[TBL] [Abstract][Full Text] [Related]
29. Combined intravitreal melphalan and intravenous/intra-arterial chemotherapy for retinoblastoma with vitreous seeds.
Lee JH; Han JW; Hahn SM; Lyu CJ; Kim DJ; Lee SC
Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):391-4. PubMed ID: 26511530
[TBL] [Abstract][Full Text] [Related]
30. Complete regression of retinoblastoma following intra-arterial chemotherapy.
Ni N; Shields CL; Bianciotto CG; Jabbour PM; Rosenwasser RH; Shields JA
J Pediatr Ophthalmol Strabismus; 2011 Jun; 48 Online():e23-5. PubMed ID: 21634361
[TBL] [Abstract][Full Text] [Related]
31. [Short-term efficacy of intravitreal injection of melphalan for refractory vitreous seeding from retinoblastoma].
Xue K; Ren H; Zhang R; Yuan YF; Qian J
Zhonghua Yan Ke Za Zhi; 2017 Aug; 53(8):570-574. PubMed ID: 28851196
[No Abstract] [Full Text] [Related]
32. Intravitreal chemotherapy in the management of vitreous disease in retinoblastoma.
Kiratli H; Koç İ; Varan A; Akyüz C
Eur J Ophthalmol; 2017 Jun; 27(4):423-427. PubMed ID: 28106239
[TBL] [Abstract][Full Text] [Related]
33. Melphalan toxicity following treatment of retinoblastoma identified by pattern electroretinogram.
Liasis A; Paez-Escamilla M; Gruszewski J; Singh AD; Nischal KK
Ophthalmic Genet; 2023 Aug; 44(4):385-388. PubMed ID: 36330605
[TBL] [Abstract][Full Text] [Related]
34. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications.
Munier FL; Gaillard MC; Balmer A; Soliman S; Podilsky G; Moulin AP; Beck-Popovic M
Br J Ophthalmol; 2012 Aug; 96(8):1078-83. PubMed ID: 22694968
[TBL] [Abstract][Full Text] [Related]
35. Heterochromia following intravitreal chemotherapy in two cases.
Camp DA; Lally SE; Shields CL
J AAPOS; 2019 Aug; 23(4):241-243. PubMed ID: 31039403
[TBL] [Abstract][Full Text] [Related]
36. Low retinal toxicity of intravitreal carboplatin associated with good retinal tumour control in transgenic murine retinoblastoma.
Lemaître S; Poyer F; Fréneaux P; Leboucher S; Doz F; Cassoux N; Thomas CD
Clin Exp Ophthalmol; 2020 May; 48(4):500-511. PubMed ID: 31872542
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal injection of melphalan for intraocular retinoblastoma.
Suzuki S; Aihara Y; Fujiwara M; Sano S; Kaneko A
Jpn J Ophthalmol; 2015 May; 59(3):164-72. PubMed ID: 25808017
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal Lower-Dose (20 µg) Melphalan for Persistent or Recurrent Retinoblastoma Vitreous Seeds.
Tuncer S; Balcı Ö; Tanyıldız B; Kebudi R; Shields CL
Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):942-8. PubMed ID: 26469234
[TBL] [Abstract][Full Text] [Related]
39. The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan.
Francis JH; Abramson DH; Gaillard MC; Marr BP; Beck-Popovic M; Munier FL
Ophthalmology; 2015 Jun; 122(6):1173-9. PubMed ID: 25795478
[TBL] [Abstract][Full Text] [Related]
40. Rabbit Model of Intra-Arterial Chemotherapy Toxicity Demonstrates Retinopathy and Vasculopathy Related to Drug and Dose, Not Procedure or Approach.
Daniels AB; Froehler MT; Nunnally AH; Pierce JM; Bozic I; Stone CA; Santapuram PR; Tao YK; Boyd KL; Himmel LE; Chen SC; Du L; Friedman DL; Richmond A
Invest Ophthalmol Vis Sci; 2019 Mar; 60(4):954-964. PubMed ID: 30882851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
